A2δ ligands gabapentin and pregabalin: Future implications in daily clinical practice

Hippokratia

Volumn 14, Issue 2, 2010, Pages 71-75

  Tzellos, T G ^a   Papazisis, G ^a   Toulis, K A ^a   Sardeli, C ^a   Kouvelas, D ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

2 ligands; Gabapentin; Lyrica; Neurontin; Pregabalin

Indexed keywords

ALPHA2 DELTA LIGAND; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BACLOFEN; CYCLOBENZAPRINE; ESTROGEN; GABAPENTIN; KETAMINE; NARCOTIC ANALGESIC AGENT; PLACEBO; PREGABALIN; PRIMIDONE; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL;

ADJUVANT THERAPY; ANXIETY DISORDER; ARTERIAL PRESSURE; ATAXIA; BRADYCARDIA; BREAST CANCER; CALCIUM CURRENT; CARDIOVASCULAR DISEASE; CHRONIC PAIN; CLINICAL PRACTICE; CLINICAL TRIAL; COMPLEX PARTIAL SEIZURE; COST EFFECTIVENESS ANALYSIS; DIABETIC NEUROPATHY; DIZZINESS; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ESSENTIAL TREMOR; EVIDENCE BASED MEDICINE; EXCITATORY POSTSYNAPTIC POTENTIAL; FATIGUE; FIBROMYALGIA; FOCAL EPILEPSY; GABAERGIC SYSTEM; HOT FLUSH; HUMAN; INHIBITION KINETICS; NEUROPATHIC PAIN; NONHUMAN; ORGAN INJURY; POSTHERPETIC NEURALGIA; REVIEW; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SPINAL CORD INJURY; TACHYCARDIA; UNSPECIFIED SIDE EFFECT; UNSTEADINESS;

EID: 77950787869     PISSN: 11084189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Maneuf YP, Hughes J, McKnight AT. Gabapentin inhibits the substance P-facilitated K(+)-evoked release of [(3)H]glutamate from rat caudial trigeminal nucleus slices. Pain. 2001; 93: 191-196.
2. Gore M, Sadosky A, Tai KS, Stacey B. A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings. Clin Ther. 2007; 29: 1655-1670.
3. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998; 280: 1831-1836.
4. Mathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N, et al. Efficacy of gabapentin in migraine prophylaxis. Headache. 2001; 41: 119-128.
5. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004; 110: 628-638.
6. Dworkin RH, Corbin AE, Young JP Jr, Sharma U, LaMoreaux L, Bockbrader H, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003; 60: 1274-1283.
7. Tassone DM, Boyce E, Guyer J, Nuzum D. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther. 2007; 29: 26-48.
8. Errante LD, Williamson A, Spencer DD, Petroff OA. Gabapentin and vigabatrin increase GABA in the human neocortical slice. Epilepsy Res. 2002; 49: 203-210.
9. McClelland D, Evans RM, Barkworth L, Martin DJ, Scott RH. A study comparing the actions of gabapentin and pregabalin on the electrophysiological properties of cultured DRG neurones from neonatal rats. BMC Pharmacol. 2004; 4: 14.
10. Fink K, Dooley DJ, Meder WP, Suman-Chauhan N, Duffy S, Clusmann H, et al. Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology. 2002; 42: 229-236.
11. Taylor CP. The biology and pharmacology of calcium channel alpha2-delta proteins Pfizer Satellite Symposium to the 2003 Society for Neuroscience Meeting. Sheraton New Orleans Hotel, New Orleans, LA November 10, 2003. CNS Drug Rev. 2004; 10: 183-188.
12. Urban MO, Ren K, Park KT, Campbell B, Anker N, Stearns B, et al. Comparison of the antinociceptive profiles of gabapentin and 3-methylgabapentin in rat models of acute and persistent pain: implications for mechanism of action. J Pharmacol Exp Ther. 2005; 313: 1209-1216.
13. Pan HL, Eisenach JC, Chen SR. Gabapentin suppresses ectopic nerve discharges and reverses allodynia in neuropathic rats. J Pharmacol Exp Ther. 1999; 288: 1026-1030.
14. Hao JX, Xu XJ, Urban L, Wiesenfeld-Hallin Z. Repeated administration of systemic gabapentin alleviates allodynia-like behaviors in spinally injured rats. Neurosci Lett. 2000; 280: 211-214.
15. Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res. 1998; 29: 233-249.
16. Dooley DJ, Donovan CM, Pugsley TA. Stimulus-dependent modulation of [(3)H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther. 2000; 295: 1086-1093.
17. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990; 33: 160-172.
18. Mease PJ, Clauw DJ, Arnold LM, Goldenberg DL, Witter J, Williams DA, et al. Fibromyalgia syndrome. J Rheumatol. 2005; 32: 2270-2277.
19. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995; 38: 19-28.
20. Marder WD, Meenan RF, Felson DT, Reichlin M, Birnbaum NS, Croft JD, et al. The present and future adequacy of rheumatology manpower. A study of health care needs and physician supply. Arthritis Rheum. 1991; 34: 1209-1217.
21. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA. 2004; 292: 2388-2395.
22. Tzellos T, Toulis K, Goulis D, Papazisis G, Zampeli V, Vakfari A, et al. Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis. Journal of Clinical Pharmacy and Therapeutics. 2009; 34: 1-18.
23. Moldofsky H. Sleep and musculoskeletal pain. Am J Med. 1986; 81: 85-89.
24. Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord. 2007; 8: 27.
25. Crofford LJ, Mease PJ, Simpson SL, Young JP, Jr., Martin SA, Haig GM, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain. 2008; 136: 419-431.
26. Carette S, Bell MJ, Reynolds WJ, Haraoui B, McCain GA, Bykerk VP, et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial. Arthritis Rheum. 1994; 37: 32-40.
27. Mellegers MA, Furlan AD, Mailis A. Gabapentin for neuropathic pain: systematic review of controlled and uncontrolled literature. Clin J Pain. 2001; 17: 284-295.
28. Jensen TS, Gottrup H, Sindrup SH, Bach FW. The clinical picture of neuropathic pain. Eur J Pharmacol. 2001; 429: 1-11.
29. Cairns DM, Adkins RH, Scott MD. Pain and depression in acute traumatic spinal cord injury: origins of chronic problematic pain? Arch Phys Med Rehabil. 1996; 77: 329-335.
30. Warms CA, Turner JA, Marshall HM, Cardenas DD. Treatments for chronic pain associated with spinal cord injuries: many are tried, few are helpful. Clin J Pain. 2002; 18: 154-163.
31. Gbandi R, Kanonidou Z. Management of patients with transection injury of the spinal cord. Hippokratia. 2005; 9: 26-34.
32. Tzellos TG, Papazisis G, Amaniti E, Kouvelas D. Efficacy of pregabalin and gabapentin for neuropathic pain in spinal-cord injury: an evidence-based evaluation of the literature. Eur J Clin Pharmacol. 2008; 64: 851-858.
33. Levendoglu F, Ogun CO, Ozerbil O, Ogun TC, Ugurlu H. Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury. Spine 2004; 29: 743-751.
34. Freedman RR, Norton D, Woodward S, Cornelissen G. Core body temperature and circadian rhythm of hot flashes in menopausal women. J Clin Endocrinol Metab. 1995; 80: 2354-2358.
35. Bachmann GA. Vasomotor flushes in menopausal women. Am J Obstet Gynecol. 1999; 180: 312-316.
36. Carpenter JS, Andrykowski MA, Cordova M, Cunningham L, Studts J, McGrath P, et al. Hot flashes in postmenopausal women treated for breast carcinoma: prevalence, severity, correlates, management, and relation to quality of life. Cancer. 1998; 82: 1682-1691.
37. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288: 321-333.
38. Suvanto-Luukkonen E, Koivunen R, Sundstrom H, Bloigu R, Karjalainen E, Haiva-Mallinen L, et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause. 2005; 12: 18-26.
39. Edlund MJ, Fortney JC, Reaves CM, Pyne JM, Mittal D. Beliefs about depression and depression treatment among depressed veterans. Med Care. 2008; 46: 581-589.
40. Toulis KA, Tzellos T, Kouvelas D, Goulis DG. Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis. Clin Ther. 2009; 31: 221-235.
41. Pandya KJ, Morrow GR, Roscoe JA, Zhao H, Hickok JT, Pajon E, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet. 2005; 366: 818-824.
42. Loprinzi CL, Kugler JW, Barton DL, Dueck AC, Tschetter LK, Nelimark RA, et al. Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5. J Clin Oncol. 2007; 25: 308-312.
43. Loprinzi L, Barton DL, Sloan JA, Zahasky KM, Smith DA, Pruthi S, et al. Pilot evaluation of gabapentin for treating hot flashes. Mayo Clin Proc. 2002; 77: 1159-1163.
44. Pandya KJ, Thummala AR, Griggs JJ, Rosenblatt JD, Sahasrabudhe DM, Guttuso TJ, et al. Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer. Breast Cancer Res Treat. 2004; 83: 87-89.
45. Guttuso T, Jr., Kurlan R, McDermott MP, Kieburtz K. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2003; 101: 337-345.
46. Butt DA, Lock M, Lewis JE, Ross S, Moineddin R. Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial. Menopause. 2008; 15: 310-318.
47. Reddy SY, Warner H, Guttuso T, Jr., Messing S, DiGrazio W, Thornburg L, et al. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol. 2006; 108: 41-48.
48. Pregabalin in treating women with hot flashes. July 2009. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00702949?term=pregabalin+hot+flushes&rank=1.
49. Louis ED, Ottman R, Hauser WA. How common is the most common adult movement disorder? estimates of the prevalence of essential tremor throughout the world. Mov Disord. 1998; 13: 5-10.
50. Koller W, Biary N, Cone S. Disability in essential tremor: effect of treatment. Neurology. 1986; 36: 1001-1004.
51. Hubble JP, Busenbark KL, Koller WC. Essential tremor. Clin Neuropharmacol. 1989;12: 453-482.
52. Koller WC, Vetere-Overfield B. Acute and chronic effects of propranolol and primidone in essential tremor. Neurology. 1989; 39: 1587-1588.
53. Gironell A, Kulisevsky J, Barbanoj M, Lopez-Villegas D, Hernandez G, Pascual-Sedano B. A randomized placebo-controlled comparative trial of gabapentin and propranolol in essential tremor. Arch Neurol. 1999; 56: 475-480.
54. Ondo W, Hunter C, Vuong KD, Schwartz K, Jankovic J. Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial. Mov Disord. 2000; 15: 678-682.
55. Pahwa R, Lyons K, Hubble JP, Busenbark K, Rienerth JD, Pahwa A, et al. Double-blind controlled trial of gabapentin in essential tremor. Mov Disord. 1998; 13: 465-467.
56. Zesiewicz TA, Elble R, Louis ED, Hauser RA, Sullivan KL, Dewey RB, Jr., et al. Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2005; 64: 2008-2020.
57. Zesiewicz TA, Ward CL, Hauser RA, Salemi JL, Siraj S, Wilson MC, et al. A pilot, double-blind, placebo-controlled trial of pregabalin (Lyrica) in the treatment of essential tremor. Mov Disord. 2007; 22: 1660-1663.
58. Pregabalin (Lyrica) for the treatment of essential tremor. July 2009. Available from:http://www.clinicaltrials.gov/ct2/show/NCT00584376?term=pregabalin+essential+tremor&rank=1.
59. Siddall PJ, Cousins MJ, Otte A, Griesing T, Chambers R, Murphy TK. Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology. 2006; 67: 1792-1800.
60. Vranken JH, Dijkgraaf MG, Kruis MR, van der Vegt MH, Hollmann MW, Heesen M. Pregabalin in patients with central neuropathic pain: a randomized, double-blind, placebo-controlled trial of a flexible-dose regimen. Pain. 2008; 136: 150-157.
61. Rintala DH, Holmes SA, Courtade D, Fiess RN, Tastard LV, Loubser PG. Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury. Arch Phys Med Rehabil. 2007; 88: 1547-1560.
62. Watson CP. The treatment of neuropathic pain: antidepressants and opioids. Clin J Pain. 2000; 16: 49-55.
63. Katz N, Benoit C. Opioids for neuropathic pain. Curr Pain Headache Rep. 2005; 9: 153-160.